Table 2 Associations between intake of fish, meat and meat mutagens with risk of endometrial cancer in the NIH-AARP Diet and Health Studya

From: A prospective investigation of fish, meat and cooking-related carcinogens with endometrial cancer incidence

  Q1 Q2 Q3 Q4 Q5
  N (cases) HR N (cases) HR (95% CI) N (cases) HR (95% CI) N (cases) HR (95% CI) N (cases) HR (95% CI) P -trend
Red meat
Model 1 281 1.00 270 0.88 (0.74–1.04) 310 0.97 (0.82–1.14) 279 0.84 (0.71–1.00) 307 0.89 (0.75–1.05) 0.293
Model 2 271 1.00 265 0.90 (0.76–1.07) 295 0.97 (0.82–1.14) 271 0.85 (0.72–1.01) 302 0.91 (0.77–1.08) 0.450
White meat
Model 1 260 1.00 284 1.05 (0.89–1.24) 307 1.12 (0.95–1.32) 313 1.14 (0.96–1.34) 283 1.00 (0.85–1.19) 0.955
Model 2 249 1.00 281 1.07 (0.90–1.28) 299 1.13 (0.96–1.34) 305 1.14 (0.97–1.36) 270 0.98 (0.83–1.17) 0.660
Processed meat
Model 1 269 1.00 272 0.94 (0.79–1.11) 296 0.97 (0.82–1.15) 281 0.89 (0.75–1.06) 329 1.01 (0.85–1.19) 0.660
Model 2 255 1.00 268 0.97 (0.82–1.16) 289 1.00 (0.84–1.19) 273 0.91 (0.76–1.09) 319 1.02 (0.86–1.21) 0.695
Total fish
Model 1 280 1.00 280 0.99 (0.84–1.17) 263 0.91 (0.77–1.08) 310 1.09 (0.92–1.28) 315 1.11 (0.94–1.30) 0.059
Model 2 269 1.00 274 1.01 (0.85–1.19) 255 0.92 (0.77–1.09) 304 1.11 (0.94–1.30) 303 1.10 (0.93–1.29) 0.095
Fried fish
Model 1 455 1.00 99 0.93 (0.74–1.16) 303 1.02 (0.88–1.17) 273 0.89 (0.77–1.04) 318 0.98 (0.85–1.13) 0.797
Model 2 444 1.00 96 0.94 (0.75–1.18) 297 1.02 (0.88–1.18) 263 0.90 (0.77–1.05) 305 0.99 (0.85–1.15) 0.914
PhIP
 Model 1 174 1.00 212 1.17 (0.96–1.43) 214 1.19 (0.97–1.45) 176 0.96 (0.78–1.19) 190 1.01 (0.82–1.25) 0.286
 Model 2 170 1.00 207 1.17 (0.95–1.43) 209 1.20 (0.98–1.47) 167 0.95 (0.77–1.18) 185 1.02 (0.82–1.26) 0.303
MeIQx
 Model 1 179 1.00 183 1.00 (0.81–1.23) 202 1.07 (0.87–1.30) 212 1.08 (0.88–1.32) 190 0.92 (0.75–1.14) 0.321
 Model 2 169 1.00 182 1.06 (0.86–1.31) 197 1.12 (0.91–1.38) 207 1.13 (0.92–1.39) 183 0.96 (0.77–1.18) 0.346
DiMeIQx
 Model 1 353 1.00 10 0.89 (0.48–1.67) 173 0.94 (0.79–1.13) 202 1.05 (0.88–1.25) 228 1.14 (0.96–1.35) 0.066
 Model 2 342 1.00 9 0.84 (0.43–1.64) 167 0.95 (0.79–1.14) 198 1.07 (0.90–1.28) 222 1.15 (0.97–1.37) 0.049
BaP
 Model 1 165 1.00 221 1.28 (1.04–1.56) 209 1.19 (0.97–1.46) 204 1.18 (0.96–1.45) 167 0.97 (0.78–1.20) 0.060
 Model 2 160 1.00 212 1.27 (1.04–1.56) 206 1.22 (0.99–1.50) 200 1.22 (0.99–1.50) 160 0.98 (0.79–1.22) 0.084
  1. Abbreviations: BaP=benzo(a)pyrene; CI=confidence interval; DiMeIQx=2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline; HR=hazard ratio; HT=hormone therapy; MeIQx=2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline; PhIP=2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
  2. aModel 1 was adjusted for age (<55, 55–59, 60–64, 65–69 or 70 years); Body mass index (<18.5, 18.5-<25, 25-<30, 30 kg m–2); smoking status (never, former, current); continuous total energy intake and was mutually adjusted for other meat intake. Model 2 was additionally adjusted age at menarche (10, 11-12, 13 years), age at first child’s birth(<20, 20–29, 30 years), parity (nulliparous, 1-2 children, 3 children), age at menopause (still menstruating, <44, 44–49, 50–54, 55 years), HT use (never, ever), oral contraceptive use (never, ever), diabetes (yes, no) and physical activity (never/rarely, 1–3 times per month, 1 time per week).